title: Clinical and scientific aspects related to biosimilars in inflammatory bowel diseases (IBD): position document of the Belgian IBD Research & Development Group (BIRD).
authors.forename: S
authors.initials: S
authors.lastname: Vermeire
authors.forename: E
authors.initials: E
authors.lastname: Louis
authors.forename: O
authors.initials: O
authors.lastname: Dewit
authors.forename: D
authors.initials: D
authors.lastname: Franchimont
authors.forename: T
authors.initials: T
authors.lastname: Moreels
authors.forename: M
authors.initials: M
authors.lastname: Ferrante
authors.forename: J-F
authors.initials: JF
authors.lastname: Rahier
authors.forename: Ph
authors.initials: P
authors.lastname: Van Hootegem
authors.forename: M
authors.initials: M
authors.lastname: De Vos
authors.forename: F
authors.initials: F
authors.lastname: Mana
authors.forename: F
authors.initials: F
authors.lastname: Baert
mesh_terms: D000068879:Adalimumab / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001530:Belgium; D059451:Biosimilar Pharmaceuticals / Q000627:therapeutic use*; D017277:Drug Approval; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D000069285:Infliximab / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D059451:Biosimilar Pharmaceuticals; D005765:Gastrointestinal Agents; D014409:Tumor Necrosis Factor-alpha; C529000:golimumab; D000069285:Infliximab; D000068879:Adalimumab